Investigation on the Potential Application of Na-Attapulgite as an Excipient in Domperidone Sustained-Release Tablets

In this study, Na-attapulgite was explored as an excipient to prepare domperidone sustained-release tablets and test them in accordance with United States Pharmacopoeia requirements. Fourier transform infrared spectroscopy (FTIR), X-ray powder diffraction (XRD) and differential scanning calorimetry (DSC) were employed to explore the compatibility between Na-attapulgite and domperidone. The XRD and DSC show no interaction between the drug and Na-attapulgite. The FTIR spectrum indicates a shift in the absorption of N-H in the drug molecule, which can be explained by the hydrogen bonding interaction between the N-H in the DOM molecule and the -OH on the surface of Na-ATP. The diameter, hardness, friability and drug content of the tablets were measured, and they all met the relevant requirements of the United States Pharmacopoeia. In addition, the tablets with Na-attapulgite as excipient exhibit a better release performance within the release time of 12 h. These results demonstrate that the domperidone sustained-release tablets have been successfully prepared by using Na-attapulgite as an excipient. The doping of Na-ATP in domperidone sustained-release tablets improves the cytocompatibility. Moreover, with the increase of Na-ATP content, cells proliferate remarkably and cell activity is significantly enhanced.

Automated summary

Na-attapulgite was successfully used as an excipient to prepare domperidone sustained-release tablets in this study. The compatibility between Na-attapulgite and domperidone was investigated, and it was found that there was no interaction between the two. The tablets met the requirements of the United States Pharmacopoeia and showed improved release performance when Na-attapulgite was used as an excipient. Additionally, the doping of Na-attapulgite enhanced cell compatibility and cell activity.